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Abstract
Background: Two Phase III randomized controlled clinical trials were conducted to assess the
efficacy, safety, and tolerability of weekly subcutaneous administration of efalizumab for the
treatment of psoriasis. Patient reported measures of psoriasis-related functionality and health-
related quality of life and of psoriasis-related symptom assessments were included as part of the
trials.
Objective: To assess the reliability, validity, and responsiveness of the patient reported outcome
measures that were used in the trials – the Dermatology Life Quality Index (DLQI), the Psoriasis
Symptom Assessment (PSA) Scale, and two itch measures, a Visual Analog Scale (VAS) and the
National Psoriasis Foundation (NPF) itch measure.
Methods: Subjects aged 18 to 70 years with moderate to severe psoriasis for at least 6 months
were recruited into the two clinical trials (n = 1095). Internal consistency reliability was evaluated
for all patient reported outcomes at baseline and at 12 weeks. Construct validity was evaluated by
relations among the different patient reported outcomes and between the patient reported
outcomes and the clinical assessments (Psoriasis Area and Severity Index; Overall Lesion Severity
Scale; Physician's Global Assessment of Change) assessed at baseline and at 12 weeks, as was the
change over the course of the 12 week portion of the trial.
Results: Internal consistency reliability ranged from 0.86 to 0.95 for the patient reported outcome
measures. The patient reported outcome measures were all shown to have significant construct
validity with respect to each other and with respect to the clinical assessments. The four measures
also demonstrated significant responsiveness to change in underlying clinical status of the patients
over the course of the trial, as measured by the independently assessed clinical outcomes.
Conclusions:  The DLQI, the PSA, VAS, and the NPF are considered useful tools for the
measurement of dermatology-related limitations of functional ability and the frequency, severity
and impact of psoriasis symptoms on patients' lives and psoriasis-related quality of life.
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Psoriasis has been demonstrated to have substantial
impacts on dermatology-related functional limitations
and health-related quality of life (HRQL) [1–7]. The itch-
ing and other physical symptoms associated with psoria-
sis negatively impacts patients' functional well-being and
their social relationships. Concerns about the appearance
of one's skin can result in distress [8], worry, and embar-
rassment leading to restrictions in social, recreational, and
work activities. Sexual functioning has also been demon-
strated to be adversely impacted by psoriasis [9]. Psoriasis
results in economic burden in terms of direct cost of care
[10] and in terms of indirect cost of lost productivity at
work and home [11]. In addition, some psoriasis treat-
ment regimens have time costs associated with adminis-
tration, such as doctor visits for ultra-violet treatment or
safety monitoring for topical administration. Studies of
psoriasis patients will often include both physician-
assessed clinical endpoints and dermatology-specific
patient-reported HRQL and limitations of functional abil-
ity to obtain a more comprehensive view of the impacts of
the disease and its treatment on the patient [12]. A
number of measures have been developed for measuring
psoriasis-related HRQL and functional limitations [2].
Along with measuring patient-reported HRQL and derma-
tology-specific functional limitations, measuring patient-
reported psoriasis symptoms is an important adjunct to
clinical assessments of the disease. In fact, for some symp-
tom domains, such as itch or pain associated with psori-
atic plaques, the patient report is the primary source of
assessment. Some disease specific measures of HRQL used
in dermatology contain items that assess patient-reported
symptoms as well [13–17].
The purpose of the current analyses was to examine the
psychometric properties of four patient-reported meas-
ures – a psoriasis symptom assessment measure, two sin-
gle-item itch scales, and one dermatology-specific HRQL
measure – when used in a moderate to severe psoriasis
population. Specifically, the psychometric properties
investigated were reliability, validity, and the responsive-
ness to underlying clinical change for each of the patient-
reported measures. The HRQL measure under investiga-
tion is the Dermatology Life Quality Index (DLQI), a val-
idated questionnaire that was developed as a practical
measure for use in dermatology clinical settings [17]. The
first symptom measure, the Psoriasis Symptom Assess-
ment (PSA) scale, was adapted from the symptom scale of
the validated Skindex-29 [14], a measure intended to
assess the effects of skin disease on the patients' HRQL.
The single-item itch measures were an itch Visual Analog
Scale (VAS), used in Study A, and the itch scale from the
National Psoriasis Foundation [18] – the NPF itch scale,
used in Study B. These four patient-reported measures
were used in two randomized clinical trials of a new ther-
apy for moderate to severe psoriasis patients (combined n
= 1095) thereby providing a substantial data-set for in-
depth examination of their psychometric properties. Evi-
dence supporting psychometric qualities such as reliabil-
ity, validity, responsiveness for patient-reported outcomes
is needed for clinical trials comparing therapies and to
support claims of HRQL and symptom benefit [19].
Methods
The data for the analyses came from two Phase III rand-
omized, double-blind, parallel group, placebo-controlled,
multi-center clinical trials that were conducted to assess
the efficacy, safety, and tolerability of weekly subcutane-
ous administration of efalizumab for the treatment of
psoriasis. The two studies are labeled Study A and Study B,
and were similar in design. Details of these studies are
reported elsewhere [20]. Subjects were randomized to
receive either the study drug or placebo. Both studies
involved an initial twelve week treatment period that
included assessments at baseline and after twelve weeks;
the primary safety and efficacy endpoints of the trials
focused on this twelve week treatment period. The analy-
ses described in the present report do not evaluate treat-
ment effects. This report focuses on a blinded
examination of psychometric properties of the patient-
reported instruments included in the two clinical studies.
Subjects signed informed consent forms, and the study
complied with FDA Good Clinical Practices, Health Pro-
tection Branch guidelines, and all other applicable ethical,
legal, and regulatory requirements.
Subjects and Inclusion Criteria
Subjects volunteering for the study were screened for eli-
gibility. Subjects had to have been classified with at least
moderate psoriasis (e.g., at least 10% of body surface area
covered with plaques and screening PASI score ≥ 12) for at
least six months, and had to have been between the age of
18 and 70. Excluded from the study were patients with
any of a number of concomitant diseases or allergies to
the class of medications used in the trials, as well as preg-
nant or lactating females. There were 498 subjects in Study
A and 597 subjects in Study B. Both studies recruited sub-
jects from multiple clinical centers located throughout the
United States and Canada.
Clinical Measures
Psoriasis Area and Severity Index (PASI)
The PASI [21] is frequently used as an endpoint in psoria-
sis clinical trials [22], and the proportion of subjects
achieving PASI-75, defined as ≥ 75% improvement in
PASI score from baseline, was the primary efficacy end-
point in both Study A and Study B. The PASI is a compos-
ite index indicating the severity of the three main
characteristics of psoriatic plaques (erythema, scaling, and
thickness) weighted by the amount of coverage of theseHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/53
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plaques in the four main body areas (i.e., head, trunk,
upper extremities, and lower extremities). PASI scores can
range from 0 to 72, with higher scores indicating greater
severity.
Overall Lesion Severity Scale (OLS)
The OLS is a physician global rating of psoriasis severity at
a given point in time. The physician assigns a number
from 0 ("clear") to 5 ("very severe") indicating his/her
judgment of psoriasis severity. The physician is guided in
this judgment by the status of three characteristics of the
plaque (i.e., plaque elevation, scaling and erythema). The
OLS was developed for use in these and related clinical
trials.
Physician's Global Assessment of Change (PGA)
The PGA corresponds to the physician's global assessment
of changes in all psoriatic lesions compared to the base-
line condition (using photographs from baseline to aid in
making the assessment). The possible scores are "Cleared"
(100% improvement); "Excellent" (75%–99% improve-
ment); "Good" (50%–74% improvement); "Fair" (25%–
49% improvement); "Slight" (1%–24% improvement);
"Unchanged"; and "Worse". For purposes of the analyses
in this report, these categories were scored from 5 to neg-
ative 1, corresponding to "excellent" to "worse",
respectively.
Patient-Reported Outcome Measures
Four patient reported outcome measures were used in
these studies: the PSA, DLQI, and two measures of itching.
Psoriasis Symptom Assessment (PSA) Scale
The PSA contains eight symptom questions related to pso-
riasis, to which the patient responds twice, once in terms
of frequency of occurrence (4-point scale, ranging from
"always" to "never"), and once in terms of troublesome-
ness/ bothersomeness (4-point scale, ranging from "a
great deal" to "not at all") [14]. Two scores are derived
from the PSA, one for frequency and one for severity (e.g.,
from the troublesomeness/ bothersomeness ratings).
Each PSA score ranges from 0 to 32, with higher scores
indicating worse psoriasis symptoms.
The PSA was adapted from the symptom scale of the vali-
dated Skindex-29 [14,15]. The first seven symptoms of the
PSA are identical to the original Skindex-29 symptoms
scale. An eighth item ("Your skin was scaling") was added
based upon clinical judgment as to the importance of this
symptom and based on a review of results from earlier
efalizumab clinical trials. The PSA requires the subject to
rate both frequency and severity over the previous two
weeks. The Skindex-29 requires the subject to respond
only in terms of frequency, and the subject is asked to
respond to each item in terms of their perception at
present (e.g., "my skin hurts").
Dermatology Life Quality Index
The DLQI was developed as a simple and practical ques-
tionnaire for use in dermatology clinical settings to assess
limitations related to the impact of skin disease [17]. The
instrument contains ten items dealing with the subject's
skin. The ten items were based upon the most commonly
identified impacts upon dermatology-specific HRQL that
were elicited from patients with skin disease. The score on
the DLQI has a possible range of 0 to 30, with 30 corre-
sponding to the worst HRQL. The DLQI has evidence sup-
porting reliability and validity when used in a
dermatology setting [17]. The DLQI was developed to
contain six subscale scores: symptoms and feelings; daily
activities; leisure; work/school; personal relationships;
and treatment.
Itch Measures
Study A and Study B used slightly different single-item
measures to assess itchiness. Study A used a single item
itch VAS, anchored by the terms "no itching" at the 0
point to "severe itching" at the 10 end of the scale. Sub-
jects were asked to respond in terms of their itching "at the
present time." Study B used the itch scale from the
National Psoriasis Foundation score [18]. The itch scale is
a single, 6-point Likert-type item assessing itching over the
past 24 hours, with responses from 0 ("no itching") to 5
("severe, constant itching, distressing; frequent sleep dis-
turbance; interferes with activities").
Statistical Methods
The psychometric properties of the patient-reported out-
come measures were assessed to determine the different
instrument's reliability, validity and responsiveness
[23,24]. For the PSA, internal consistency reliability – i.e.,
the extent to which items on a scale are all measuring the
same concept – was evaluated for the original 7 item and
new 8 item scale, and for both the PSA frequency and
severity scores. Internal consistency reliability was evalu-
ated for all the multi-item scores using Cronbach's coeffi-
cient α statistic [25].
Validity represents the extent to which the instrument
actually measures the construct it is intended to measure
[23]. Validity of patient-reported outcomes is assessed by
specifying and testing hypotheses about the relationship
between the patient-reported outcome measures and
other independent measures (e.g., severity of disease, cli-
nician rated clinical status) and other health related meas-
ures. The strength of the correlation between measures
intended to assess similar concepts was examined. Specif-
ically, the correlation of the single-item itch scale (i.e.,
VAS or NPF itch) with item 3 on the PSA ("your skinHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/53
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itched") was compared to the correlation of the itch scale
with other items on the PSA. The correlation of the PSA
score with the symptom scale of the DLQI was compared
with its correlation with the other DLQI scales, with the
hypothesis that as a measure of patient-reported symp-
toms, the PSA would correlate higher with this DLQI scale
than with the other five DLQI scales. To further investigate
the validity of the scales, an assessment was made of the
relationship between the patient-reported outcomes and
the clinical measures, both at baseline and at week 12.
Moderately strong correlations between the clinician rated
and patient-reported symptom measures, and between
clinician rated symptoms and the DLQI were expected.
Pearson product-moment correlations were used to assess
relationships between the clinical and patient-reported
outcome measures.
Responsiveness of a patient-reported outcome deals with
the extent to which changes in the scores are associated
with changes in the underlying clinical status of the sub-
ject over some defined time period. Two approaches were
used to assess the responsiveness of the patient-reported
outcome measures. First, changes in these measures from
baseline to week 12 were correlated with the changes in
the physician-assessed clinical measures over this 12 week
period, as well as with the physician's global assessment
of change at week 12. The second approach to assessing
responsiveness involved categorizing subjects into three
groups based on the change in their PASI scores from
baseline to week 12: PASI improved ≥ 75%; PASI
improved  ≥ 50% – 74.9%; and PASI got worse or
improved < 50%. Analyses of variance were performed
among these three groups on the changes from baseline to
the 12-week endpoint in the patient-reported outcome
measures.
Analyses were performed on blinded data, that is, the sta-
tus of the subject with respect to his/her assigned treat-
ment group was not known. Given that Study A and Study
B were independently conducted studies; the results of the
two clinical trials were analyzed separately. Two-sided
tests with alpha = 0.05 were used to determine statistical
significance, and there was no adjustment for multiple
statistical tests.
Results
The average age of the 498 subjects enrolled in Study A
was 44.1 (s.d. = 12.0) and of the 597 subjects in Study B
was 45.6 (s.d.= 12.7). Males comprised 72.3% of the sam-
ple in Study A and 64.8% of the sample in Study B. The
baseline PASI scores for Study A and Study B were 18.84
(7.05) and 20.01 (8.35), respectively; and the baseline
OLS scores for the two studies were 3.46 (0.63) and 3.31
(0.85), respectively. These scores indicate that the subjects
in both studies had moderate to severe psoriasis (e.g., the
OLS score of 3 corresponds to physician ratings of "mod-
erate" psoriasis, and a 4 corresponds to "severe"
psoriasis).
The means, standard deviations, and reliability coeffi-
cients (Cronbach's coefficient α) of the patient reported
outcomes are shown in Table 1. Complete baseline and
12 week data were available for 89.7–90.5% of the sub-
jects in Study A and for 93.5–97.4% of the subjects in
Study B. In general, the PSA, DLQI and VAS itch, and NPS
itch scores decreased over the 12-week studies.
The internal consistency reliability coefficients of all the
patient-reported measures are satisfactory, ranging from
approximately 0.86 to 0.95 (see Table 1). Internal consist-
ency reliabilities were somewhat better at the 12-week fol-
low-up in both studies. For the PSA, no substantive
differences in reliabilities were observed between the 7-
item and 8-item versions.
Table 1: Means, Standard Deviations, and Coefficient α for Patient Reported Outcome Measures, Baseline and Week 12
STUDY A STUDY B
Baseline Week 12 Baseline Week 12
Patient-reported outcome 
measure
N Mean (s.d.) Coefficient α N Mean (s.d.) Coefficient α N Mean (s.d.) Coefficient α N Mean (s.d.) Coefficient α
PSA Frequency: 8-item scale 493 13.21 (5.07) 0.858 446 8.22 (5.57) 0.927 594 13.79 (5.22) 0.875 572 8.51 (6.24) 0.940
PSA Frequency: 7-item scale 493 n/a 0.865 446 n/a 0.922 594 n/a 0.876 572 n/a 0.936
PSA Severity: 8-item scale 494 14.08 (5.55) 0.874 445 8.55 (6.42) 0.942 595 14.38 (5.62) 0.891 573 8.66 (6.71) 0.946
PSA Severity: 7-item scale 494 n/a 0.874 445 n/a 0.939 595 n/a 0.889 573 n/a 0.941
DLQI 483 11.75 (6.80) 0.871 437 6.69 (6.51) 0.921 586 12.18 (6.71) 0.869 571 7.07 (6.74) 0.919
VAS Itch 497 5.90 (2.68) n/a1 446 3.74 (3.03) n/a1 -- - -- -
NPS Itch - - - - - - 597 3.05 (1.41) n/a1 558 1.80 (1.50) n/a1
1 Coefficient α is not applicable for single-item scalesHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/53
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The correlations at baseline and week 12 among the
patient reported outcomes are summarized in Table 2.
The PSA frequency and severity scores correlate in the
range of 0.59 to 0.63 with the DLQI total score at baseline
and in the range of 0.78 to 0.79 at 12 weeks. As hypothe-
sized, the PSA frequency and severity scores correlate most
strongly with the DLQI symptoms and feelings subscale
than with the other DLQI subscales. The PSA scores corre-
late in the range of 0.59 to 0.82 with the two itch scores.
The correlations between scores on the DLQI and scores
on the VAS (Study A) and NPF (Study B) itch scales are sig-
nificant (see Table 3). The DLQI symptoms and feelings
subscale correlates strongly and significantly with the itch
measures. Combined, these data demonstrate that the itch
scale correlates more highly with the patient-reported out-
come measures that deal specifically with the symptom of
itching (e.g., PSA; DLQI symptoms and feelings subscale)
than with the other patient-reported outcome measures.
The relationship between the patient-reported outcomes
and the physician-based clinical assessments was also
evaluated. The patient reported outcome measures – the
PSA, the DLQI, and the itch scales – all correlate signifi-
cantly with both the PASI score and the OLS (Table 4).
These correlations were significantly stronger at the end of
Table 2: Correlations Between the PSA Frequency and Severity Scores and the DLQI Total and Scale Scores and the Itch Measures, 
Baseline and Week 12
STUDY A STUDY B
Baseline Week 12 Baseline Week 12
Scale/Subscale PSA Freq PSA Severity PSA Freq PSA Severity PSA Freq PSA Severity PSA Freq PSA Severity
DLQI Total Scale 0.59 0.61 0.78 0.79 0.62 0.63 0.78 0.79
DLQI 
Symptoms 
and Feelings 
Subscale
0.62 0.64 0.83 0.84 0.66 0.68 0.83 0.84
DLQI Daily 
Activities 
Subscale
0.44 0.46 0.65 0.67 0.48 0.48 0.68 0.69
DLQI Leisure 
Subscale
0.38 0.40 0.60 0.61 0.43 0.44 0.61 0.60
DLQI Work 
and School 
Subscale
0.45 0.48 0.58 0.60 0.41 0.40 0.55 0.54
DLQI 
Personal 
Relationship 
Subscale
0.37 0.37 0.55 0.54 0.42 0.42 0.53 0.54
DLQI 
Treatment 
Subscale
0.43 0.42 0.66 0.67 0.38 0.39 0.60 0.62
NPF Itch Scale n/a n/a n/a n/a 0.67 0.68 0.81 0.82
VAS Itch Scale 0.60 0.59 0.78 0.80 n/a n/a n/a n/a
All correlations are significant at p < 0.001
Table 3: Correlations Among DLQI Scores and Itch Measures, Baseline and Week 12
STUDY A STUDY B
Baseline Week 12 Baseline Week 12
VAS Itch Scale VAS Itch Scale NPF Itch Scale NPF Itch Scale
DLQI Total Scale 0.45 0.66 0.52 0.73
DLQI Symptoms and Feelings 
Subscale
0.57 0.74 0.59 0.79
DLQI Daily Activities Subscale 0.32 0.56 0.39 0.62
DLQI Leisure Subscale 0.26 0.49 0.34 0.55
DLQI Work and School 
Subscale
0.28 0.45 0.35 0.54
DLQI Personal Relationship 
Subscale
0.26 0.45 0.34 0.47
DLQI Treatment Subscale 0.30 0.56 0.32 0.54
All correlations are significant at p < 0.001Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/53
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the study than at baseline. For example, the PSA severity
score at baseline was correlated 0.19, in both studies, with
PASI scores, but at 12 weeks this correlation increased to
0.57 in Study A and 0.53 in Study B. Similar patterns of
small to moderate correlations were observed for the two
itch scales and the PASI and OLS.
The responsiveness of the patient-reported outcomes to
clinical change was evaluated using the two approaches
discussed in the methods section. The correlations
between the change scores for the clinical and patient-
reported outcomes over the 12-week period are reported
in Table 5. The patient-reported outcomes used in these
studies demonstrate very good associations with changes
in clinical status. Specifically, the correlations of changes
in the PSA scores, the NPF itch score, and the DLQI total
score with the changes in the PASI and OLS clinical meas-
ures and with the PGA are all highly significant and in the
0.44 to 0.57 range. The DLQI subscale demonstrating the
strongest relationship with changes in PASI or OLS scores
was the symptoms and feelings subscale. The other sub-
scales, which focus on other HRQL impacts of psoriasis,
are not quite as strongly correlated with clinical changes,
as might be expected. The 8-item PSA was slightly more
correlated to changes in clinical status than the original 7-
item version (see Table 5). There was also a moderate and
significant correlation between change in the patient-
reported outcome measures and the PGA of change in the
patient's psoriatic symptoms.
The second approach to assessing responsiveness of the
patient reported outcomes relied upon the classification
of subjects into three categories based upon the change in
PASI scores from baseline to the end of the 12-week treat-
ment period. The results of analysis of variance to assess
differences among the three groups categorized by % of
PASI improvement from baseline to week 12 are summa-
rized in Table 6. There were significant differences among
the groups on all the outcome measures, and in all cases,
the post hoc analyses indicated significant differences
between all pair-wise comparisons of groups. For all
patient-reported outcomes there was a consistent trend of
greater improvement on the respective patient reported
outcome corresponding to greater improvement on the
PASI.
Discussion and Conclusions
Two randomized clinical trials for a new therapy for pso-
riasis provided the opportunity to evaluate the reliability,
validity, and responsiveness to change in clinical status of
several patient-reported outcome measures. The results of
the present study provide evidence supporting the reliabil-
ity, construct validity and responsiveness of the PSA, the
DLQI, and the two itch scales.
Table 4: Correlations Between Patient Reported Measures and the Psoriasis Area and Severity Index (PASI) and Overall Lesion 
Severity Scale (OLS) at Baseline and at Week 12.
STUDY A STUDY B
Baseline Week 12 Baseline Week 12
Patient-
reported 
outcome 
measure
PASI OLS PASI OLS PASI OLS PASI OLS
PSA Frequency 0.19 0.19 0.57 0.60 0.19 0.22 0.53 0.58
PSA Severity 0.16 0.16 0.55 0.59 0.19 0.23 0.54 0.58
DLQI Total Scale 0.20 0.18 0.51 0.48 0.25 0.19 0.59 0.58
DLQI 
Symptoms 
and Feelings 
Subscale
0.17 0.16 0.54 0.55 0.18 0.18 0.56 0.61
DLQI Daily 
Activities 
Subscale
0.10b 0.12a 0.44 0.44 0.20 0.12a 0.51 0.50
DLQI Leisure 
Subscale
0.11b 0.08 0.39 0.32 0.21 0.13a 0.47 0.46
DLQI Work 
and School 
Subscale
0.18 0.15 0.37 0.34 0.19 0.16 0.35 0.32
DLQI 
Personal 
Relationship 
Subscale
0.13a 0.13a 0.31 0.29 0.11a 0.10b 0.41 0.36
DLQI 
Treatment 
Subscale
0.27 0.19 0.48 0.43 0.29 0.24 0.53 0.47
NPF Itch Scale n/a n/a n/a n/a 0.16 0.17 0.52 0.54
VAS Itch Scale 0.14a 0.14a 0.53 0.54 n/a n/a n/a n/a
All correlations are significant at p < 0.001 unless otherwise noted ap < 0.01. bp < 0.05.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/53
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Table 5: Correlations Among Change Scores for PSA Frequency and Severity Scores, DLQI Scores and NPF Itch Scores with Change 
Scores on Clinical Measures and with the Physician's Global Assessment of Change (PGA) at Week 12
STUDY A STUDY B
Difference Scores: 
Baseline to Week 12
Clinical Measure Clinical Measure
Scale/Subscale PASI OLS PGA1 PASI OLS PGA1
Total Score PSA 
Frequency – 8 item 
scale
0.49 0.47 0.54 0.53 0.54 0.57
Total Score PSA 
Frequency – 7 item 
scale
0.46 0.44 0.51 0.51 0.51 0.54
Total Score PSA 
Severity – 8 item scale
0.50 0.49 0.55 0.52 0.53 0.57
Total Score PSA 
Severity – 7 item scale
0.47 0.47 0.53 0.51 0.51 0.55
DLQI Total Scale 0.47 0.43 0.46 0.54 0.46 0.53
DLQI Symptoms 
and Feelings 
Subscale
0.53 0.48 0.52 0.52 0.51 0.56
DLQI Daily 
Activities Subscale
0.38 0.37 0.40 0.44 0.35 0.43
DLQI Leisure 
Subscale
0.34 0.29 0.33 0.36 0.27 0.31
DLQI Work and 
School Subscale
0.18 0.16 0.20 0.27 0.26 0.30
DLQI Personal 
Relationship 
Subscale
0.23 0.20 0.25 0.32 0.29 0.33
DLQI Treatment 
Subscale
0.38 0.32 0.35 0.44 0.36 0.38
NPF Itch Scale n/a n/a n/a 0.46 0.44 0.52
VAS Itch Scale 0.50 0.47 0.51 n/a n/a n/a
All correlations are significant at p < 0.001 1 PGA is assessed only at end of treatment
Table 6: Analyses of Variance of Patient Reported Outcome Measures Among Three Groups of PASI Improvement Scores:≥ 75%; 
Between 50% and 75%; and < 50%.
STUDY A STUDY B
Mean Change Score (N) Mean Change Score (N)
Outcome Measure <50% ≥50% and 
<75%
≥75% F statistic p value < 50% ≥50% and 
<75%
≥75% F statistic p value
PSA Frequency (8 items) 2.38 (232) 6.48 (97) 8.75 (110) 61.71 <0.0001 2.35 (269) 7.16 (149) 9.71 (125) 85.65 <0.0001
PSA Frequency (7 items) 1.90 (232) 5.15 (97) 7.12 (111) 49.81 <0.0001 1.90 (269) 5.94 (149) 7.98 (125) 72.61 <0.0001
PSA Severity (8 items) 2.45 (231) 7.05 (97) 9.93 (111) 69.06 <0.0001 2.52 (271) 7.87 (149) 10.52 (125) 88.46 <0.0001
PSA Severity (7 items) 1.95 (231) 5.76 (97) 8.19 (111) 58.82 <0.0001 2.05 (271) 6.47 (149) 8.79 (125) 77.04 <0.0001
PSA TOTAL Scale (16 items) 4.79 (230) 13.53 (96) 18.63 (110) 69.76 <0.0001 4.88 (269) 15.03 (149) 20.23 (125) 91.77 <0.0001
DLQI TOTAL 2.48 (223) 5.33 (97) 9.57 (104) 54.61 <0.0001 2.49 (268) 6.83 (146) 10.03 (122) 75.05 <0.0001
DLQI Symptom and Feelings 0.74 (235) 1.70 (98) 2.94 (110) 69.64 <0.0001 0.79 (271) 2.14 (150) 2.95 (127) 94.27 <0.0001
DLQI Daily Activities 0.45 (234) 1.13 (98) 2.14 (110) 41.11 <0.0001 0.61 (270) 1.47 (150) 2.17 (127) 42.37 <0.0001
DLQI Leisure 0.40 (235) 0.96 (98) 1.81 (111) 27.70 <0.0001 0.60 (271) 1.08 (150) 1.89 (126) 22.34 <0.0001
DLQI Work and School 0.28 (226) 0.46 (97) 0.62 (106) 5.41a <0.0001 0.17 (269) 0.52 (147) 0.73 (123) 16.44b <0.0001
DLQI Personal Relationships 0.20 (236) 0.45 (98) 1.20 (111) 17.89 <0.0001 0.12 (271) 0.75 (150) 1.21 (126) 25.21 <0.0001
DLQI Treatment 0.22 (236) 0.65 (98) 1.05 (111) 24.90 <0.0001 0.14 (271) 0.81 (149) 1.08 (126) 41.70b <0.0001
NPF Itch Scale n/a n/a n/a n/a n/a 0.59 (273) 1.65 (150) 2.34 (127) 58.13 <0.0001
VAS Itch Scale 0.79 (235) 2.97 (98) 4.34 (111) 56.96 <0.0001 n/a n/a n/a n/a n/a
Note: Post-hoc comparisons of groups indicate all groups differ from one another for each of the measures, p < .05, unless otherwise specified. a PASI change ≥75% different from PASI 
change <50% only. b PASI change ≥75% not significantly different from middle group (PASI change ≥50% and <75%.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/53
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Although developed for a general dermatologic popula-
tion, the DLQI has been applied to patients with psoriasis.
For example, Badia et al. [26] used the DLQI in a sample
of patients with mild to moderate eczema or psoriasis
(approximately half the sample had psoriasis). Their
results on the combined sample demonstrated that the
DLQI was responsive to change, although they reported
that the great majority of change occurred in the symptom
and feeling scale of the DLQI. Zachariae et al. [27] tested
a Danish version of the DLQI on a mixed sample of
patients with dermatological diseases, including psoriasis.
They found significant relationships between DLQI scores
and physician-rated severity. Nichol et al. [28] reported a
significant relationship between the DLQI and psoriatic
symptoms in a sample enrolled in multi-center clinical tri-
als. Ellis et al. [29] used the DLQI and the SF-36 in a Phase
II clinical trial of a new treatment for psoriasis. Their
results show greater responsiveness to treatment for the
DLQI than to the SF-36. These and other studies [30,31]
support the use of the DLQI as a HRQL measure in psori-
atic populations.
The current study further establishes the reliability and
validity characteristics of the DLQI and expands on this by
demonstrating the responsiveness of the DLQI to change
in clinical status over the course of two independently
conducted clinical trials with initial treatment periods of
12 weeks. Changes in the DLQI total score, as well as in all
of the DLQI subscales, demonstrated significant and size-
able correlations with independently obtained physician-
assessed changes in the clinical status of patients. As in the
Badia et al. study [26], changes in the symptom and feel-
ings scale demonstrated the greatest association with
changes in clinical status. However, the other scales were
also very responsive. For example, the daily activities
scale, which is comprised of two items dealing with the
interference of the skin disease on activities like shopping
or with the choice of clothing, demonstrates the second
highest responsiveness to clinical changes. This indicates
that the alleviation of psoriatic symptoms, as determined
by clinical assessments, results in significant and marked
improvements to the dermatology-specific HRQL of pso-
riasis patients.
In addition to the dermatology-specific HRQL measure,
this study included patient-reported symptom scales.
Both the PSA and itch scales demonstrated responsiveness
to changes in clinical status. They also demonstrated sig-
nificant correlations with the clinical indicators obtained
at the same time period, especially so at the end of the 12-
week portion of the trial. Taken together, these data indi-
cate that patient reports of their symptoms are an impor-
tant and valid indication of clinical status.
In addition to demonstrating that the PSA is a reliable and
valid instrument for a psoriasis population, the present
study also confirms that the addition of an item on scaling
of skin specific to psoriasis to the symptom scale of the
Skindex-29, as well as slight changes in instructions to the
subjects (as described in Methods) results in good reliabil-
ity and validity, and increases its responsiveness. The 8-
symptom scale was shown to be as reliable as the 7-symp-
tom scale. In addition, the very high correlations between
the PSA frequency and severity scores would indicate that
it may not be necessary to ask both questions about the
symptoms – one measure would suffice.
The present study demonstrates the validity, reliability,
and responsiveness of several patient-reported outcome
measures in the study of psoriasis, specifically the PSA, the
DLQI and two itch scales. Although the DLQI has been
used frequently in studies of psoriasis, the results pre-
sented here represent a very broad assessment involving
the DLQI, two different itch measures, and patient-
reported symptom assessments. Moreover, the results
were derived from two independently conducted clinical
trials using a combined study population that is greater
than any other study using patient reported outcomes in
assessing the impact of a psoriasis drug on these out-
comes. The results of the psychometric analyses con-
ducted confirm that these patient-reported measures are
appropriate endpoints in clinical trials of psoriasis and
that they relate well to the clinical endpoints of PASI, OLS
and PGA. The use of patient-reported outcome measures
with demonstrably good psychometric properties is a
highly recommended when using such measures in a pso-
riatic population [32]. Based upon previous evidence and
the results of the present study, the DLQI, the PSA, the
VAS itch measure, and the NPF itch measure are consid-
ered useful tools for the measurement of dermatology-
related limitations of functional ability and the frequency,
severity and impact of psoriasis symptoms on patients'
lives. These measures provide information about the
change in subject's psoriatic symptoms that supplement
and provide assessments from a different perspective than
the clinical assessments obtained by physicians.
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